argenx NV ADR logo

argenx NV ADR(ARGX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 2 days
PROFIT SINCE LAST BUY
-2.17% ▼
LAST CLOSE
$960.04
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ARGX

11/13/2026: ARGX (2-star) has a low Upturn Star Rating. Not recommended to BUY.

argenx NV ADR is a commercial-stage global biopharmaceutical company specializing in antibody-based therapies for severe autoimmune diseases. The company's primary business strength is anchored by the successful global rollout of VYVGART, which has captured a leading position in precision immunology. Its main growth opportunity lies in label expansions across new indications and advancing a rich clinical pipeline under its Vision 2030 goals. Key risks include high product revenue concentration, heavy R&D expenditure, and emerging competition in the FcRn inhibitor space. The stock is best suited for growth-oriented investors willing to monitor clinical readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitRapid multi-year revenue scaling and a broad pipeline targeting major immunological conditions align well with growth mandates.
Momentum investorStrong fit while signal remains positiveHigh trading volume and sharp reactions to clinical catalysts and sales reports attract active momentum participants.
Value investorWeak fitTrading at high forward multiples reflecting aggressive growth expectations limits traditional deep-value appeal.
Dividend investorWeak fitThe company retains earnings to fund research and does not pay a regular dividend.
Low-risk investorMixed fitHigh stock price volatility and binary clinical trial risks pose challenges for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech market sentiment and clinical trial headlines regularly induce sharp stock price swings.
Valuation riskMedium / highLofty valuation multiples leave little room for operational execution missteps or pipeline setbacks.
Competition risk (FcRn and targeted biologic rivalry)Medium / highRival firms are advancing competing therapies that could threaten long-term market share dominance.
Business qualityStrongProprietary technology, robust gross margins, and proven commercial execution reflect high structural quality.
Dividend incomeLow / noneNo cash distribution is provided, making the stock unsuitable for income-focused strategies.
Execution riskMediumSuccessful execution of broad global clinical trials and new product launches is critical to meeting long-term targets.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 60.37B USD
Price to earnings Ratio 33.25
1Y Target Price 1144.74
Price to earnings Ratio 33.25
1Y Target Price 1144.74
Volume (30-day avg) 469.7K shares
Beta -0.06
52 Weeks Range 661.85 - 1072.75
Updated Date 11/15/2026
52 Weeks Range 661.85 - 1072.75
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 28.87

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 60.6%
Avg. Invested days 56
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ARGX receives a 4-star rating, supported by strong unit economics, solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ARGX has solid overall fundamentals (4 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+55.1%) and strong cash generation (FCF margin 20.3%) are partially offset by very low insider ownership of 0.04%.

Financial Health Rating

★★★★★
ARGX's financial health is supported by strong cash strength, including free-cash-flow generation (20.3% of revenue). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ARGX's strongest growth driver at +659.0% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+89.6%, strong) and earnings growth (+55.1%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 46.4% and approximately 2482.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.04%, which materially reduces the ownership score.

Top 5 Institutional Investors

FMR Inc 8.32%
T. Rowe Price Associates, Inc. 4.26%
Jupiter Topco LLC 3.93%
Capital World Investors 3.50%
Artisan Partners Limited Partnership 2.40%

Unit Economics (Per $1K Revenue)

★★★★★
ARGX generates approximately $891 of gross profit, $254 of operating income, and $203 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.05% (Tax Credit)

Quantitative Style Profile

★★★★★
ARGX has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Immunotherapy Sales (VYVGART & VYVGART Hytrulo)Global sales of efgartigimod formulations prescribed for severe autoimmune indications across the United States, Europe, Japan, and other regions.Virtually all current revenues come from the commercial success and expanding adoption of VYVGART.
Collaboration and License AgreementsUpfront payments, milestone fees, and royalties generated from codevelopment partnerships using argenx's antibody platforms.Secondary revenue stream that validates proprietary drug discovery platforms through partnerships with other drug makers.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-22
When Before Market
Estimate 7.44
Actual 7.8

Profitability

Profit Margin 31.73%
Operating Margin (TTM) 31.94%

Management Effectiveness

Return on Assets (TTM) 11.64%
Return on Equity (TTM) 23.64%

Valuation

Trailing PE 33.25
Forward PE 28.82
Enterprise Value 55.90B
Price to Sales(TTM) 10.21
Enterprise Value 55.90B
Price to Sales(TTM) 10.21
Enterprise Value to Revenue 9.6
Enterprise Value to EBITDA 29.38
Shares Outstanding 62.89M
Shares Floating 1.56B
Shares Outstanding 62.89M
Shares Floating 1.56B
Percent Insiders 0.04
Percent Institutions 46.38

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.